Two offers share one name here, and they are not variations of each other. One is a copay program; the other is a price list. Which one applies depends on a single question about a plan, and the answer changes the monthly bill by hundreds. The drug itself is priced in orforglipron price.
| Your commercial plan | What you pay | What the card absorbs |
|---|---|---|
| Covers Foundayo | As little as $25 per 1-month fill | Up to $100 a month and $1,000 a year |
| Does not cover Foundayo | $149 to $299 a month, by dose | Up to $520 a month on the lowest doses |
| Government program of any kind | The card cannot be used | Nothing |
Both tiers ask for commercial drug insurance[1]. Neither is open to anyone enrolled in Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, a Department of Defense plan, the VA, TRICARE or a state prescription assistance program[1].
Both also require a US or Puerto Rico address and an age of at least 18[1]. And both stop at 10 fills in a calendar year[1].
The government exclusion is not a marketing choice. The federal anti-kickback statute reaches a manufacturer that offers a coupon to induce the purchase of a drug a federal health program pays for[5]. An inspector general review found that manufacturers’ own safeguards may not stop every coupon reaching one[5].
The number LillyDirect does not print
The product page shows a price for each dose and, under the top two, says only that regular prices will apply if the prescription is not refilled in time[3]. The savings terms print those regular prices in full[1].
The ladder is slow by design, which is what makes the refill clock bite. The label moves a patient up only after at least 30 days on the current dose, to a maximum of 17.2 mg once daily[4].
| Dose | Price today | Regular price | Difference |
|---|---|---|---|
| 0.8 mg | $149 | $149 | None |
| 2.5 mg | $149 | $199 | $50 higher |
| 5.5 mg | $199 | $299 | $100 higher |
| 9 mg | $299 | $299 | None |
| 14.5 mg | $299 | $349 | $50 higher |
| 17.2 mg | $299 | $349 | $50 higher |
Two of these reductions run on a clock and two run on a behavior. The terms date the 2.5 mg and 5.5 mg reductions to December 31, 2026[1].
The 14.5 mg and 17.2 mg doses hold $299 only when the next purchase is completed within 45 days of the previous delivery[1]. A first purchase gets that price automatically; keeping it is the part that takes attention[1].
Why a plan can make the card unusable
The terms describe alternate funding programs: arrangements in which a plan requires a member to apply to the manufacturer’s program as a condition of coverage[1].
A member of such a plan is not eligible for the card and is prohibited from using it, and the terms ask them to say so[1]. It is worth asking a benefits administrator about this before counting on any manufacturer discount.
The Medicare route runs somewhere else entirely
Medicare enrollees cannot use the card, but they are not without a route. Eligible Part D enrollees pay $50 a month for Foundayo through the Medicare GLP-1 Bridge[2].
The demonstration runs from July 1, 2026 through December 31, 2027 and covers weight management only[2]. An enrollee whose prescription is for type 2 diabetes, sleep apnea or fatty liver disease goes through their plan instead[2].
How that compares with the other maker’s tablet is in Foundayo vs the Wegovy pill, and against the injection in Foundayo vs Zepbound.
What a month actually costs once the card is in
The card sets a drug price, not a total. A telehealth visit, a delivery charge and any lab work sit outside it, and they are the parts a card never touches.
The all-in monthly calculator adds those to whichever tier applies. For how the same question is handled by the other makers, see the Zepbound savings card and the Wegovy savings card.